Katagiri T, Miyazawa K, Uchida Y, Hayashi S, Iwama H, Shyohji N, Kawakubo K, Shimamoto T, Inatomi Y, Kuriyama Y, Yaguchi M, Nehashi Y, Ohyashiki K, Toyama K
First Department of Internal Medicine, Tokyo Medical University.
Rinsho Ketsueki. 1998 Dec;39(12):1149-56.
Three patients with chronic myeloid leukemia (CML) in blastic transformation were treated with G-CSF plus middle dose cytosine arabinoside (Ara-C). G-CSF was administered (150 mg, s.c. or 300 mg, d.i.v./day) 24 hr prior to Ara-C (2-3 g/body, 6 hour d.i.v. for 2-5 days) and continued until the peripheral neutrophil count rose above 1,000/microlitre. As a supplement, VP-16 (80 mg/m2, for 2 days) was administered as warranted to control the growth of blastic cells. All 3 patients survived for more than 12 months with a favorable performance status. Normal karyotypes were detected in 2 of the patients after chemotherapy. One of those patients in paticular demonstrated normal bone marrow findings with the almost complete disappearance of the Ph-positive clone. In vitro cultures of peroxidase-negative CML blastic cells revealed that G-CSF stimulated the induction of blastic cells into the cell cycle and that blastic cell apoptosis was more pronounced in cells cultured with G-CSF plus Ara-C than with G-CSF or Ara-C alone. G-CSF plus middle dose Ara-C therapy appears to be a strong candidate for the treatment of CML in blastic transformation with a poor prognosis.
3例慢性粒细胞白血病(CML)急变期患者接受了粒细胞集落刺激因子(G-CSF)加中剂量阿糖胞苷(Ara-C)治疗。在给予Ara-C(2-3 g/体,分6小时给予,共2-5天)前24小时给予G-CSF(150 mg,皮下注射或300 mg,静脉滴注/天),并持续用药至外周血中性粒细胞计数升至1000/微升以上。作为补充,根据需要给予足叶乙甙(VP-16,80 mg/m²,共2天)以控制原始细胞的生长。所有3例患者均存活超过12个月,且一般状况良好。化疗后2例患者检测到正常核型。其中1例患者尤其表现出正常的骨髓检查结果,Ph阳性克隆几乎完全消失。对过氧化物酶阴性的CML原始细胞进行体外培养发现,G-CSF可刺激原始细胞进入细胞周期,且与单独使用G-CSF或Ara-C相比,在G-CSF加Ara-C培养的细胞中,原始细胞凋亡更为明显。G-CSF加中剂量Ara-C疗法似乎是治疗预后不良的CML急变期的有力候选方案。